Atty Dkt. No.: AERX-080CIP2

USSN: 10/685,746

AMENDMENTS TO THE CLAIMS:

1. (Previously Presented) A method of treating erectile dysfunction in a patient, comprising the steps of:

diagnosing a human male patient as having erectile dysfunction;
aerosolizing a formulation comprising sildenafil;
inhaling the aerosolized formulation into the lungs of the human male patient; and
allowing particles comprising sildenafil to deposit on lung tissue, and enter the patient's
circulatory system in an amount sufficient to treat the erectile dysfunction of the human male patient.

- 2. (Original) The method of claim 1, further comprising: administering a bolus dose of an androgenic hormone to the patient.
- 3. (Original) The method of claim 2, wherein the administering of the androgenic hormone is by:

aerosolizing a formulation comprised of an androgenic hormone; inhaling aerosolized androgenic hormone; and allowing the androgenic hormone to deposit on lung tissue.

- 4. (Original) The method of claim 3, wherein the androgenic hormone is selected from the group consisting of testosterone and dihydrotestosterone.
- 5. (Original) The method of claim 1, wherein the aerosolized particles are comprised of particles having a diameter in a range of from about 1 to about 5 microns.
- 6. (Original) The method of claim 1, wherein the formulation further comprises a testosterone.
- 7. (Currently Amended) A method of claim 19, wherein the formulation comprises a composition selected from the group consisting of a PDE5 inhibitor, a growth hormone-releasing peptide receptor agonist, a 5-hydroxytryptamine receptor agonist, a dopamine receptor agonist,

Atty Dkt. No.: AERX-080CIP2

USSN: 10/685,746

a melanocortin receptor agonist, an α -adrenoceptor antagonist, alprostadil, papaverine, phentolamine, vasoactive intestinal peptide, guanylyl cyclases, a rho-kinase antagonist, oxytocin, an oxytocin receptor agonist, Θ an inhibitor of neuropeptide Y, Θ and a combination thereof.

- 8. (Previously Presented) The method of claim 1 or 7, wherein an erection is realized in less then 30 minutes.
- 9. (Previously Presented) The method of claim 1 or 7, wherein an erection is realized in less than 20 minutes.
- 10. (Previously Presented) The method of claim 1 or 7, wherein an erection is realized in less than 10 minutes.
 - 11. (Original) The method of claim 1 or 7, wherein the formulation is a liquid formulation.
 - 12. (Original) The method of claim 1 or 7, wherein the formulation is a dry powder.
- 13. (Original) The method of claim 1 or 7, wherein the formulation comprises a pressurized propellant.

14. - 18. (Canceled)

19. (Previously Presented) A method of treating erectile dysfunction in a patient, comprising the steps of:

diagnosing a human male patient as having erectile dysfunction;

aerosolizing a formulation comprising a vasodilator;

inhaling the aerosolized formulation into the lungs of the human male patient; and allowing particles comprising the vasodilator to deposit on lung tissue and enter the patient's circulatory system in an amount sufficient to treat the erectile dysfunction of the human male patient.

Atty Dkt. No.: AERX-080CIP2

USSN: 10/685,746

20. (Previously Presented) The method of claim 1, wherein the formulation comprises 25 mg of sildenafil.

- 21. (Previously Presented) The method of claim 1, wherein the formulation comprises 25 to 100 mg of sildenafil.
- 22. (Previously Presented) The method of claim 19, wherein the vasodilator is sildenafil and the formulation comprises 25 mg of sildenafil.
- 23. (Previously Presented) The method of claim 19, wherein the vasodilator is sildenafil and the formulation comprises 25 to 100 mg of sildenafil.
- 24. (Previously Presented) A kit for the treatment of low libido in a woman and erectile dysfunction in a man, comprising:
 - a hand-held device for the aerosolized delivery of a formulation;
 - a plurality of containers of an aerosolized formulation comprising sildenafil; and
 - a plurality of container of aerosolizable testosterone.
- 25. (Previously Presented) The kit of claim 24, wherein each of the containers of sildenafil comprises 25 mg of aerosolizable sildenafil.
- 26. (Previously Presented) The kit of claim 24, wherein each of the containers of sildenafil comprises 25 mg to 10 mg of aerosolizable sildenafil.